Patent · US Active

Compounds and compositions as protein kinase inhibitors

USRE49556E1 · kind E1 · reissue

0Cited by
26References
13Claims
0Family size

Assignee

Inventors

Key dates

Filing dateJul 15, 2021
Grant dateJun 20, 2023
Priority date
Expiry dateJul 15, 2041

Classification

  • Technology area (CPC —)General

Abstract

The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of B-Raf.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.